Illumina (NASDAQ:ILMN) Director Keith Meister Sells 225,067 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 225,067 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total value of $32,758,501.85. Following the completion of the transaction, the director owned 3,604,441 shares of the company’s stock, valued at $524,626,387.55. The trade was a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Illumina Stock Performance

Illumina stock opened at $143.24 on Friday. The firm has a market capitalization of $21.67 billion, a P/E ratio of 26.04, a PEG ratio of 2.40 and a beta of 1.42. The stock has a fifty day moving average price of $128.31 and a 200 day moving average price of $129.43. Illumina, Inc. has a 52 week low of $78.55 and a 52 week high of $155.53. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current year.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Empowered Funds LLC grew its stake in shares of Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Illumina in the second quarter valued at about $621,000. CW Advisors LLC acquired a new stake in shares of Illumina in the second quarter valued at about $275,000. Marshall Wace LLP grew its stake in shares of Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after buying an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC grew its stake in shares of Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after buying an additional 1,748 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ILMN shares. UBS Group reiterated a “neutral” rating and issued a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Citigroup upped their target price on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Piper Sandler dropped their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Finally, JPMorgan Chase & Co. upped their price target on Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $137.75.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.